IBB - Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent May, 27 2022 09:59 AM iShares Biotechnology ETF Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in. For further details see: Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent